Bone Density Conservation Agents
"Bone Density Conservation Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
| Descriptor ID |
D050071
|
| MeSH Number(s) |
D27.505.696.242
|
| Concept/Terms |
Antiresorptive Agents- Antiresorptive Agents
- Bone Resorption Inhibitors
- Inhibitors, Bone Resorption
- Resorption Inhibitors, Bone
- Bone Resorption Inhibitory Agents
- Antiresorptive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Bone Density Conservation Agents".
Below are MeSH descriptors whose meaning is more specific than "Bone Density Conservation Agents".
This graph shows the total number of publications written about "Bone Density Conservation Agents" by people in this website by year, and whether "Bone Density Conservation Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 1 | 2 |
| 2007 | 3 | 0 | 3 |
| 2008 | 0 | 1 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 1 | 3 |
| 2012 | 0 | 1 | 1 |
| 2014 | 4 | 1 | 5 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bone Density Conservation Agents" by people in Profiles.
-
Wang B, Qian JY, Tang TT, Lin LL, Yu N, Guo HL, Ni WJ, Lv LL, Wen Y, Li ZL, Wu M, Cao JY, Liu BC. VDR/Atg3 Axis Regulates Slit Diaphragm to Tight Junction Transition via p62-Mediated Autophagy Pathway in Diabetic Nephropathy. Diabetes. 2021 11; 70(11):2639-2651.
-
Bauer C, le Saux O, Pomozi V, Aherrahrou R, Kriesen R, St?lting S, Liebers A, Kessler T, Schunkert H, Erdmann J, Aherrahrou Z. Etidronate prevents dystrophic cardiac calcification by inhibiting macrophage aggregation. Sci Rep. 2018 04 11; 8(1):5812.
-
Ferguson S, Feudjo Tepie M, Taylor A, Roddam A, Critchlow C, Iqbal M, Spangler L, Bayly J. The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK: a study of patient records from the UK Clinical Practice Research Datalink. J Eval Clin Pract. 2016 Feb; 22(1):31-39.
-
Li L, Roddam A, Ferguson S, Feudjo-Tepie M, Taylor A, Jick S. Switch patterns of osteoporosis medication and its impact on persistence among postmenopausal women in the U.K. General Practice Research Database. Menopause. 2014 Oct; 21(10):1106-13.
-
Strong AL, Ohlstein JF, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Gimble JM, Burow ME, Wang G, Bunnell BA. Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanisms. Stem Cell Res Ther. 2014 Aug 28; 5(4):105.
-
Uyanne J, Calhoun CC, Le AD. Antiresorptive drug-related osteonecrosis of the jaw. Dent Clin North Am. 2014 Apr; 58(2):369-84.
-
Fontenot HB, Harris AL. Pharmacologic management of osteoporosis. J Obstet Gynecol Neonatal Nurs. 2014 Mar-Apr; 43(2):236-45; quiz E20-1.
-
D?az-Correa LM, Ram?rez-Garc?a LM, Castro-Santana LE, Vil? LM. Osteoporosis knowledge in patients with a first fragility fracture in Puerto Rico. Bol Asoc Med P R. 2014; 106(1):6-10.
-
Li L, Roddam A, Gitlin M, Taylor A, Shepherd S, Shearer A, Jick S. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Menopause. 2012 Jan; 19(1):33-40.
-
L?pez-L?pez L, Vil? LM. Atypical subtrochanteric fractures associated with long-term use of bisphosphonates. P R Health Sci J. 2011 Dec; 30(4):211.